"Researchers are hopeful about the potential for a novel agent in high-risk prostate cancer" states Tony Berberabe, MPh in his published article for Cure Magazine on June 23rd, 2016

In this blog PCRI presents an interview from our contributing partner, Prostatepedia. 

Prostatepedia spoke at length with Dr. Laurence Klotz about why testosterone levels are significant in prostate cancer. Dr. Laurence Klotz is an esteemed Urological Oncologist from the University of Toronto. He is one of the driving forces behind the development of active surveillance as a viable approach for men with slow-growing, non-aggressive prostate cancer. Here is the interview:

Dr.Kevin Nead authored an article published in the Journal of Clinical Oncology this month.  It created a media sensation and generated multiple calls to the PCRIHelpline.  Last week, three separate articles about this topic were posted on the Yahoo home page at the same time.

LDR (low dose rate) brachytherapy for prostate cancer is more commonly known as seed implants. You may be familiar with this treatment option but for those of you who may be new to the confusing world of prostate cancer treatment, seed implants involve the insertion of small radioactive pellets or seeds into the prostate by transrectal ultrasound guidance, in order to deliver a focused dose of radiation to the prostate.

Given enzalutamide’s unique and multi-targeted mechanism of action, its once a day oral administration, avoidance of accompanying requirement of a steroid, and its established safety and efficacy data, it appears to be a very promising therapy. Future studies should investigate both combination strategies with other approved prostate cancer drugs, as well as the potential role of enzalutamide in earlier stages of both CRPC and androgen-sensitive prostate cancer.